---

Patient Summary - Châu Thị Bích Điệp

---

Patient Demographics

• Name: Châu Thị Bích Điệp
• DOB: 16/05/1971 (Age: 55)
• Gender: Female
• Address: Ấp 1, Xã Vĩnh Lộc, Hóc Môn, TP.HCM
• BHYT (Health Insurance): GD479793671770379026
• Admission No.: 26/014363 | PID: 70131126012722
• Admitted: 22/06/2026 at 07:18 via Emergency Department
• Admitting Dept: Khoa Nội tiết - Tổng hợp (Endocrinology - General)
• Room 8, Bed 33

---

Diagnoses (ICD Codes)

---

Vital Signs at Admission (22/06/2026, 07:18)

---

Nursing Assessment (23/06/2026, 08:00)

---

Lab Results (22/06/2026)

Suppressed TSH with normal FT4 suggests subclinical or early hyperthyroidism (consistent with E05 diagnosis)

• Result: 211 mg/dL - significantly elevated (hyperglycemia)

---

Abdominal Ultrasound (22/06/2026 14:16)

• Liver: Normal size, smooth surface, even echogenicity
• Gallbladder: Right - no stones, not dilated; Left - no stones
• Bile ducts: Wall 3mm, normal caliber, no stones
• Pancreas: Normal
• Spleen: Normal
• Bladder: No stones, no free fluid
• Uterus: Small (atrophied - consistent with post-menopause)
• Conclusion: No abnormal findings currently

---

Treatment Plan (22-23/06/2026)

• Blood pressure, pulse, temperature
• Bedside capillary glucose checks
• Lab tests: Electrolytes (Na, K, Cl), FT4, TSH, AST, GOT, CBC (once)

---

Clinical Summary

1. Poorly controlled T2DM - fasting glucose 211 mg/dL at 6 AM despite being on Mixtard 30 insulin; glucosuria present
2. Hyperthyroidism (E05) - TSH critically suppressed at 0.0027 (normal 0.35-4.94); treated with Thiamazole
3. Ischemic cardiomyopathy (I25.5) - on Clopidogrel for antiplatelet protection
4. Hypertension (I10) - BP 130/60 on admission; on Irbesartan
5. Mixed hyperlipidemia (E78.2) - documented, management plan not fully visible

---

COMPLETE MEDICAL RECORD (English Translation)

TRUNG VUONG HOSPITAL

---

SECTION 1 - PATIENT IDENTIFICATION

---

SECTION 2 - REASON FOR ADMISSION

---

SECTION 3 - PAST MEDICAL HISTORY & COMORBIDITIES

• Type 2 Diabetes Mellitus (E11.9) - not currently on oral medications; previously managed with insulin
• Ischemic Cardiomyopathy (I25.5) - pre-existing cardiac disease due to myocardial ischemia
• Essential Hypertension (I10) - known, on treatment
• Hyperthyroidism / Thyrotoxicosis (E05 / Cuong Giap) - known, on treatment
• Mixed Hyperlipidemia (E78.2) - known, requiring lipid-lowering therapy

---

SECTION 4 - CLINICAL ASSESSMENT ON ADMISSION

Vital Signs (22/06/2026, 07:18)

Clinical Findings on Admission

• General: Alert, oriented, no distress. Skin and mucous membranes pink.
• Neurological: GCS 15, fully conscious, no focal deficits.
• Respiratory: Normal breathing, no oxygen required, no cough.
• Cardiovascular: Regular heart rhythm, no murmurs noted.
• Gastrointestinal: Abdomen soft, no tenderness.
• Musculoskeletal: Normal mobility, no edema documented.
• Pain level: Low.

Nursing Assessment (23/06/2026, 08:00 - Day 2)

• Vital signs: BP 120/80, Temp 37, SpO2 20/97, Weight 55/21.5
• Alert, mucous membranes pink, no wounds
• Breath sounds clear, no cough
• Heart rhythm: regular
• Abdomen: normal
• GCS: 15
• Bowel: normal; Urine: pale yellow; Sleep: 9h, good

---

SECTION 5 - INVESTIGATIONS

A. Hematology (22/06/2026)

B. Biochemistry (22/06/2026)

C. Thyroid Function (22/06/2026)

D. Capillary Blood Glucose (Point-of-Care)

E. Urinalysis (22/06/2026 - Automated)

F. Abdominal Ultrasound (22/06/2026 at 14:16)

---

SECTION 6 - DIAGNOSES (ICD-10 CODED)

---

SECTION 7 - TREATMENT (In-Hospital Medications)

7.1 - Medications (22-24 June 2026)

7.2 - Monitoring Orders

• Vital signs: Blood pressure, pulse, temperature (continuous)
• Bedside capillary blood glucose (morning before breakfast, repeat once)
• Labs (once): Electrolytes (Na, K, Cl), FT4, TSH, AST, ALT, CBC

7.3 - Diet

• DD01-Com - Diabetic diet with cooked rice (calorie-controlled, low simple sugars)

7.4 - Nursing Care Level

• Grade III (Cap 3) - standard nursing care

---

SECTION 8 - NURSING EDUCATION PROVIDED

---

SECTION 9 - CLINICAL PROGRESS

---

---

TYPE 2 DIABETES MELLITUS: DIAGNOSIS & MANAGEMENT

According to the ADA Standards of Care in Diabetes - 2026

---

1. DIAGNOSIS OF T2DM (ADA 2026)

---

2. GLYCEMIC GOALS (ADA 2026)

For Most Non-Pregnant Adults:

• HbA1c target: <7.0% - she is not elderly, no severe comorbidities that require relaxed targets
• Her morning fasting glucose of 211 mg/dL is significantly above goal; requires intensification
• Note: Hyperthyroidism causes insulin resistance and increases hepatic glucose output, complicating glycemic control - treating the thyroid disease (with Thiamazole) will itself help improve glucose levels

---

3. PHARMACOLOGIC MANAGEMENT ALGORITHM (ADA 2026)

STEP 1 - Assess for Established Cardiovascular Disease (CVD) or Organ Damage

ADA 2026 Recommendation: In patients with T2DM and established ASCVD, a GLP-1 Receptor Agonist (GLP-1 RA) with proven cardiovascular benefit (e.g., semaglutide, liraglutide) OR an SGLT2 Inhibitor (e.g., empagliflozin, dapagliflozin) with proven CV benefit should be added regardless of HbA1c level, as a Class A recommendation.

STEP 2 - First-Line Agent

STEP 3 - Insulin Therapy

ADA 2026 note on premixed insulin: Mixtard 30 (70/30 NPH/regular) provides both basal and prandial coverage in one injection, though it has less flexibility than basal-bolus. Starting dose: typically 0.1-0.2 units/kg/day or 10 units once daily, titrated by 2 units every 3 days.

Current dose of 14 IU/day is a low-moderate starting dose (0.25 units/kg) - appropriate for initiation.

STEP 4 - Full Medication Summary for This Patient vs. ADA 2026 Alignment

---

4. MONITORING RECOMMENDATIONS (ADA 2026)

---

5. NON-PHARMACOLOGIC MANAGEMENT (ADA 2026)

---

6. SPECIAL CONSIDERATIONS FOR THIS PATIENT

T2DM + Hyperthyroidism Interaction

• Increased hepatic gluconeogenesis
• Accelerated intestinal glucose absorption
• Increased insulin resistance
• Increased insulin clearance

T2DM + Ischemic Cardiomyopathy

• Reduce major adverse cardiovascular events (MACE) by ~14-26% in ASCVD patients
• Reduce hospitalizations for heart failure
• Have renal protective effects

Irbesartan (ARB) in T2DM

---

7. SUMMARY & CLINICAL RECOMMENDATIONS

Priority Actions (per ADA 2026):

1. Check HbA1c - not yet done; essential for baseline and target-setting
2. Titrate Mixtard 30 insulin upward (by 2 IU every 3 days) until fasting glucose 80-130 mg/dL
3. Titrate Metformin - increase from 750 mg to 1500 mg/day (divided doses) over 2-4 weeks as tolerated
4. Consider GLP-1 RA or SGLT2 inhibitor - given ischemic cardiomyopathy, ADA 2026 Class A recommendation
5. Recheck TSH and FT4 in 4-6 weeks on Thiamazole - adjust Thiamazole dose; once euthyroid, reassess glycemic needs
6. Urine albumin-to-creatinine ratio (ACR) - not yet obtained; order to screen for early diabetic nephropathy
7. Fundoscopy / eye exam - schedule for diabetic retinopathy screening
8. Foot examination - inspect for neuropathy and peripheral vascular disease at each visit
9. LDL cholesterol level - not measured; check lipid panel to set statin target (LDL <70 mg/dL for ASCVD)

---

---

1. CHIEF COMPLAINT - What Does the Record Actually Say?

"Ly do vao vien, van de suc khoe: Met" = Reason for admission / health problem: Fatigue/Tiredness

"Chan doan YHHD: Thap - Nguy co te nga" = Working diagnosis: Low - Risk of fall

---

2. How Do We Know She Has Ischemic Cardiomyopathy, Hypertension, and Mixed Hyperlipidemia?

These are PRE-EXISTING diagnoses listed on the admission form - NOT newly discovered from labs during this admission.

E11.9 - Benh dai thao duong khong phu thuoc insuline I25.5 - Benh co tim do thieu mau cuc bo I10 - Benh ly tang huyet ap E05 - Cuong giap E78.2 - Tang lipid mau hon hop

What labs were done during this admission that relate to each diagnosis?

Bottom Line:

• I25.5 and E78.2 are stated diagnoses from the patient's history - the records you shared do not contain an ECG, echocardiogram, cardiac enzyme results, or lipid panel to confirm them during this admission.
• I should have been clearer about this. I presented them as if they were confirmed by labs - they were not. They appear as listed ICD codes.

---

3. What Does Suppressed TSH + Normal FT4 Mean?

The Lab Values:

What This Pattern Means - The Thyroid Feedback System:

Normal:     TSH normal (0.35-4.94)  +  FT4 normal  =  Euthyroid (normal thyroid)
Overt Hyper: TSH suppressed (<0.1)  +  FT4 HIGH    =  Overt Hyperthyroidism
Subclinical: TSH suppressed (<0.1)  +  FT4 NORMAL  =  SUBCLINICAL Hyperthyroidism ← This patient
Overt Hypo:  TSH very HIGH (>10)    +  FT4 LOW     =  Overt Hypothyroidism

So This Patient Has: Subclinical Hyperthyroidism

• Often asymptomatic but can cause subtle symptoms: palpitations, slight tremor, fatigue, heat intolerance
• Increases cardiac risk: associated with atrial fibrillation (3x higher risk), and in the context of her pre-existing ischemic cardiomyopathy this is clinically significant
• Worsens diabetes control: as explained earlier - increases insulin resistance and hepatic glucose output
• Bone loss: increases fracture risk in post-menopausal women (this patient is ~55, likely peri/post-menopausal)
• Requires treatment - hence Thiamazole (Thyrozol 5 mg) was correctly prescribed

Why is it called "Subclinical"?

---

Summary of Corrections to My Earlier Report